CurrentCignaPolicy IP0183

Lyrica CR (pregabalin extended-release) coverage

Defines prior authorization and coverage criteria for pregabalin extended-release tablets (Lyrica CR) for Cigna-administered prescription benefits, including required trials of alternatives and conditions considered not medically necessary.

Policy Summary

PayerCigna

PolicyLyrica CR (pregabalin extended-release) coverage

Policy CodePolicy IP0183

Change TypeMaterial coverage updates (step therapy and prior therapy expansion)

Effective DateJul 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization and document trials of gabapentin IR or generic immediate‑release pregabalin; if brand Lyrica CR is requested, document trial and intolerance to the generic pregabalin ER.

SourceLink

POLICY UPDATE CHANGES

If brand Lyrica CR is requested, the patient must have tried generic pregabalin extended-release tablets and be unable to continue the generic due to formulation differences in inactive ingredients that would cause a significant allergy or serious adverse reaction.

Patient must have tried gabapentin immediate-release (brand Neurontin or generic) as an alternative to generic immediate-release pregabalin prior to approval of pregabalin extended-release.

1 yearTypical approval duration

2Approved uses covered (DPN, PHN)

3Listed not medically necessary uses

PA requiredUtilization requirement

Policy Summary

PayerCigna

PolicyLyrica CR (pregabalin extended-release) coverage

Policy CodePolicy IP0183

Change TypeMaterial coverage updates (step therapy and prior therapy expansion)

Effective DateJul 1, 2025

Next Review DateN/A

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Pregabalin Extended-Release (Lyrica CR)

FDA-Approved Indications (Initial Authorization)

Pregabalin extended-release tablets are considered medically necessary when ONE of the following criteria are met:

DPN (Neuropathic Pain Associated with Diabetic Peripheral Neuropathy)

A: Patient has tried gabapentin immediate-release (brand Neurontin or generic) or generic immediate-release pregabalin
Trial must be documented
B (brand specific): If brand Lyrica CR is requested, the patient meets BOTH: (i) has tried generic pregabalin extended-release tablets; AND (ii) cannot continue the generic due to a formulation difference in the inactive ingredient(s) (e.g., differences in dyes, fillers, preservatives) which, according to the prescriber, would result in a significant allergy or serious adverse reaction
Applies only when brand requested

PHN (Postherpetic Neuralgia)

A: Patient has tried gabapentin immediate-release (brand Neurontin or generic) or generic immediate-release pregabalin
Trial must be documented
B (brand specific): If brand Lyrica CR is requested, the patient meets BOTH: (i) has tried generic pregabalin extended-release tablets; AND (ii) cannot continue the generic due to a formulation difference in the inactive ingredient(s) (e.g., differences in dyes, fillers, preservatives) which, according to the prescriber, would result in a significant allergy or serious adverse reaction
Applies only when brand requested

Pregabalin extended-release tablets are approved and covered only for the FDA-labeled neuropathic pain indications described in this policy. Use of pregabalin extended-release outside those labeled neuropathic pain indications is not supported by the evidence reviewed in this policy and is addressed under the "Conditions Not Covered" section. Prior authorization is required and approval is provided for 1 year when the documented criteria for an approved indication are met; documentation must include trials of the required alternatives (gabapentin immediate-release or generic immediate-release pregabalin) and, if the brand product is requested, evidence per the brand-specific step requirement.

The following uses of pregabalin extended-release tablets are explicitly considered not medically necessary under this policy and will be denied: (1) Fibromyalgia — randomized withdrawal trial failed to demonstrate efficacy; (2) Partial onset seizures — adjunctive therapy trials failed to demonstrate efficacy; and (3) Restless legs syndrome — no data available. This list may not be all-inclusive and will be updated as new published data become available.

Coding and Related Definitions

Covered/Not covered indications (informational)mixed

No codes listed

PHN definition time threshold

PHN time threshold> 3 months from rash resolution

Source descriptionPersistence of pain of herpes zoster more than 3 months after resolution of the rash

Prevalence noteAffects approximately 13% of persons ≥ 50 years with herpes zoster

Provider Actions, Prior Authorization, and Billing

Prior Authorization

Prior Authorization Required

Prior Authorization is required for pregabalin extended‑release tablets. Approvals are provided for 1 year when coverage criteria are met.

Prior Authorization required for prescription benefit coverage of pregabalin extended‑release tablets.
Approval duration: 1 year when criteria are met.

Denial Risk

Coding/Coverage Mismatch — Denial Risk

When submitting claims, include covered diagnosis/procedure codes that align with this policy. Claims without a covered diagnosis or procedure code listed in this policy will be denied as not covered.

Claims lacking a covered diagnosis or procedure code per this policy will be denied.

Key Definitions

PHN — Postherpetic neuralgia

Definition (PHN)Postherpetic neuralgia: persistent pain of herpes zoster > 3 months after resolution of the rash

Clinical contextAdministration of antiviral agents within 72 hours of zoster onset can reduce acute illness duration and help prevent PHN

Treatment challengeNearly half of patients with PHN do not respond to any treatment

DPN — Diabetic peripheral neuropathy

Definition (DPN)Diabetic peripheral neuropathy: neuropathic pain associated with diabetes

Prevalence/contextPainful diabetic neuropathy affects about 16% of patients with diabetes; up to 50% of DPN may be asymptomatic

Background

Pregabalin extended-release tablets are an analog of gamma-aminobutyric acid (GABA) formulated for extended systemic exposure and are indicated for neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Clinical guidance and guideline documents commonly reference immediate-release gabapentin or pregabalin for neuropathic pain management, but evidence for the extended-release formulation is limited to the labeled DPN and PHN indications; efficacy has not been established for fibromyalgia or as adjunctive therapy for partial onset seizures.